The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer Meeting Abstract
| Authors: | Choueiri, T. K.; Hahn, N. M.; Alva, A. S.; Lauer, R. C.; Dreicer, R.; Picus, J.; Pili, R.; Balar, A. V.; Sonpavde, G.; Hoffman-Censits, J. H.; Guancial, E. A.; Alter, R.; Regan, M. M.; Jacobs, C.; Stewart, P. S.; Pal, S. K.; Rosenberg, J. E. |
| Abstract Title: | The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036904769 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.tps4577 |
| Notes: | Meeting Abstract: TPS4577 -- Source: Wos |
